SG10201900605SA - Humanized monoclonal antibody for inhibiting vascular endothelial lipase enzyme activity - Google Patents

Humanized monoclonal antibody for inhibiting vascular endothelial lipase enzyme activity

Info

Publication number
SG10201900605SA
SG10201900605SA SG10201900605SA SG10201900605SA SG10201900605SA SG 10201900605S A SG10201900605S A SG 10201900605SA SG 10201900605S A SG10201900605S A SG 10201900605SA SG 10201900605S A SG10201900605S A SG 10201900605SA SG 10201900605S A SG10201900605S A SG 10201900605SA
Authority
SG
Singapore
Prior art keywords
monoclonal antibody
vascular endothelial
humanized monoclonal
endothelial lipase
enzyme activity
Prior art date
Application number
SG10201900605SA
Inventor
Shoichi Naito
Hiroaki Aino
Etsuo Nakamura
Sunao Imai
Shoji Yamane
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55459146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201900605S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of SG10201900605SA publication Critical patent/SG10201900605SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Humanized monoclonal antibody for inhibiting vascular endothelial lipase enzyme activity Provided is a humanized monoclonal antibody or an antibody fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome. Figure for publication: None
SG10201900605SA 2014-09-11 2015-09-10 Humanized monoclonal antibody for inhibiting vascular endothelial lipase enzyme activity SG10201900605SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014184710 2014-09-11

Publications (1)

Publication Number Publication Date
SG10201900605SA true SG10201900605SA (en) 2019-02-27

Family

ID=55459146

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201900605SA SG10201900605SA (en) 2014-09-11 2015-09-10 Humanized monoclonal antibody for inhibiting vascular endothelial lipase enzyme activity
SG11201701762VA SG11201701762VA (en) 2014-09-11 2015-09-10 Humanized monoclonal antibody for inhibiting vascular endothelial lipase enzyme activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201701762VA SG11201701762VA (en) 2014-09-11 2015-09-10 Humanized monoclonal antibody for inhibiting vascular endothelial lipase enzyme activity

Country Status (19)

Country Link
US (2) US10570215B2 (en)
EP (1) EP3192813A4 (en)
JP (2) JP6635599B2 (en)
KR (1) KR102520286B1 (en)
CN (1) CN107074963B (en)
AR (1) AR101811A1 (en)
AU (1) AU2015313179B2 (en)
BR (1) BR112017004429A2 (en)
CA (1) CA2960994A1 (en)
CL (1) CL2017000595A1 (en)
EA (1) EA036324B1 (en)
IL (1) IL250981B (en)
MX (1) MX2017002968A (en)
MY (1) MY181835A (en)
PH (1) PH12017500461A1 (en)
SG (2) SG10201900605SA (en)
TW (2) TWI688575B (en)
WO (1) WO2016039402A1 (en)
ZA (1) ZA201702489B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107735105B (en) * 2015-06-30 2022-09-16 西雅图基因公司 anti-NTB-A antibodies and related compositions and methods
EP3652208A1 (en) * 2017-07-10 2020-05-20 Innate Pharma Siglec-9-neutralizing antibodies
TWI758558B (en) * 2017-11-10 2022-03-21 大陸商江蘇恒瑞醫藥股份有限公司 Cd96 antibody, antigen-binding fragment and pharmaceutical uses thereof
US20230045712A1 (en) * 2019-11-07 2023-02-09 Medimmune, Llc Endothelial lipase antibodies for the treatment of cardiovascular diseases
CN115297838A (en) * 2020-02-24 2022-11-04 麦迪穆医学免疫有限责任公司 Formulations of anti-endothelial lipase antibodies
WO2022095934A1 (en) * 2020-11-05 2022-05-12 上海津曼特生物科技有限公司 Anti-siglec-15 antibody and application thereof in preparing drug

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH062075B2 (en) * 1988-04-30 1994-01-12 大日本製薬株式会社 Anti-human postheparin plasma-derived lipoprotein lipase monoclonal antibody and method for producing the same
CZ299055B6 (en) * 1996-12-06 2008-04-09 Aventis Pharmaceuticals Inc. Isolated polypeptide encoded by a lipase like gene, composition having phospholipase activity, pharmaceutical composition, isolated immunizing peptide and nucleic acid, biologically compatible solution, vector, recombinant cell, formulation useable f
WO1999032611A1 (en) * 1997-12-19 1999-07-01 Progenitor, Inc. A lipase expressed in endothelial cells and methods for its use
WO2000057837A2 (en) 1999-03-26 2000-10-05 Aventis Pharmaceuticals Products Inc. Compositions and methods for effecting the levels of cholesterol
WO2013054830A1 (en) * 2011-10-12 2013-04-18 塩野義製薬株式会社 Monoclonal antibody against el, inhibiting el enzymatic activity
US9701757B2 (en) * 2013-03-14 2017-07-11 Shionogi & Co., Ltd. Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase

Also Published As

Publication number Publication date
SG11201701762VA (en) 2017-04-27
MY181835A (en) 2021-01-08
US10570215B2 (en) 2020-02-25
JP6827255B2 (en) 2021-02-10
TWI688575B (en) 2020-03-21
AR101811A1 (en) 2017-01-11
ZA201702489B (en) 2018-08-29
CL2017000595A1 (en) 2017-11-03
JPWO2016039402A1 (en) 2017-06-22
JP6635599B2 (en) 2020-01-29
AU2015313179A1 (en) 2017-03-30
EA201790590A1 (en) 2017-08-31
TW202026313A (en) 2020-07-16
CA2960994A1 (en) 2016-03-17
PH12017500461A1 (en) 2017-07-31
IL250981A0 (en) 2017-04-30
TW201613982A (en) 2016-04-16
TWI734410B (en) 2021-07-21
BR112017004429A2 (en) 2018-02-27
WO2016039402A1 (en) 2016-03-17
US20200071424A1 (en) 2020-03-05
EA036324B1 (en) 2020-10-27
MX2017002968A (en) 2017-06-15
AU2015313179B2 (en) 2020-10-22
EP3192813A4 (en) 2018-08-01
KR102520286B1 (en) 2023-04-10
CN107074963B (en) 2021-07-16
US20170260290A1 (en) 2017-09-14
EP3192813A1 (en) 2017-07-19
IL250981B (en) 2020-06-30
JP2020059743A (en) 2020-04-16
KR20170052655A (en) 2017-05-12
US11136411B2 (en) 2021-10-05
CN107074963A (en) 2017-08-18

Similar Documents

Publication Publication Date Title
SG10201900605SA (en) Humanized monoclonal antibody for inhibiting vascular endothelial lipase enzyme activity
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
MX2017001976A (en) Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1.
WO2015123423A3 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
EA201200559A1 (en) METHODS OF APPOINTMENT PYRPHENIDONE THERAPY
PH12014501122A1 (en) Methods of treatment using an antibody against interferon gamma
MX338610B (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor.
WO2012125544A3 (en) Necroptosis inhibitors and methods of use therefor
MA47362A (en) ANTI-TNF ANTIBODIES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTIVE PSORIASIC RHEUMATISM
SG10201900862WA (en) Anti-orai1 antibody
MX2022006750A (en) Masp-2 inhibitors and methods of use.
PH12018501646A1 (en) Compositions and methods for treating infections
MY193996A (en) Tripeptide compound, preparation method therefor, and application thereof
EA201600012A1 (en) METHOD OF PREVENTION AND / OR TREATMENT OF CARDIOVASCULAR DISEASES
PH12015502092A1 (en) Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
AU2018258588A8 (en) Inhibitors of TRIM33 and methods of use
MX2018000571A (en) Method for fruit thinning.
ZA202005083B (en) Solid forms of fasoracetam
EP3783022A3 (en) Anti-vegf-a antibodies and uses thereof
MX2019014773A (en) Ccl2 inhibitors.
MX2018003453A (en) Conjoint therapies with inhibitors of glucose production.